ライフサイエンスコーパス: thyroid cancer

1 se that undergoes rearrangement in papillary thyroid cancer).

2 sible increase in the incidence of childhood thyroid cancer.

3 id ultrasound is frequently used to diagnose thyroid cancer.

4 ore first-degree relatives with a history of thyroid cancer.

5 might improve the preoperative diagnosis of thyroid cancer.

6 ients with advanced papillary and anaplastic thyroid cancer.

7 ent of patients with low-risk differentiated thyroid cancer.

8 roid cancer cell lines, and rodent models of thyroid cancer.

9 es for future studies of the pathogenesis of thyroid cancer.

10 ts and harms of treatment of screen-detected thyroid cancer.

11 es, driven largely by increases in papillary thyroid cancer.

12 gy-associated pathogenesis of differentiated thyroid cancer.

13 Mount Etna in determining the high rates of thyroid cancer.

14 SF3 may be involved in the predisposition of thyroid cancer.

15 creased access to the surgical management of thyroid cancer.

16 ase-free survival in patients with papillary thyroid cancer.

17 %) died from incidentally detected medullary thyroid cancer.

18 rce (USPSTF) recommendation on screening for thyroid cancer.

19 sortilin as potential therapeutic targets in thyroid cancer.

20 ct of insurance statuses on the treatment of thyroid cancer.

21 1.1%-4.7%) for SEER distant stage papillary thyroid cancer.

22 ipating in a case-control study on papillary thyroid cancer.

23 ng (including overdiagnosis) or treatment of thyroid cancer.

24 increased rate of thyroidectomy for treating thyroid cancer.

25 ition to VEGFR and is approved for medullary thyroid cancer.

26 mortality rate for advanced-stage papillary thyroid cancer.

27 oaches, and the future of immunotherapies in thyroid cancer.

28 and metastatic progression in this model of thyroid cancer.

29 e-based therapies for patients with advanced thyroid cancer.

30 g the worldwide increase in the incidence of thyroid cancer.

31 dine effectiveness in radioiodine-refractory thyroid cancer.

32 ss aggressive and more common differentiated thyroid cancer.

33 editing as a potential therapeutic target in thyroid cancer.

34 e of and barriers to active surveillance for thyroid cancer.

35 are at increased risk for the development of thyroid cancer.

36 oplasia type 2 as well as sporadic medullary thyroid cancer.

37 esses and a promising therapeutic target for thyroid cancer.

38 ncers, and RET fusions occur rarely in other thyroid cancers.

39 ses overall, particularly of gynecologic and thyroid cancers.

40 mechanisms underlying familial and sporadic thyroid cancers.

41 nosed anaplastic and refractory or recurrent thyroid cancers.

42 s of human RAS-driven, poorly differentiated thyroid cancers.

43 ours, and a subset of malignant melanoma and thyroid cancers.

44 re malignancy that accounts for 1%-2% of all thyroid cancers.

45 inical behavior and outcome of patients with thyroid cancers.

46 mmon subsequent malignancies were breast and thyroid cancers.

47 mmune system in the pathogenesis of advanced thyroid cancers.

48 n; ETV1 in prostate; and IGF2BP3 and SIX2 in thyroid cancers.

49 thologic evaluation, 47 (36%) had incidental thyroid cancer (24 papillary, 11 malignant FNA, 5 oncocy

50 ft-tissue sarcoma (3.4; 95% CI, 1.9 to 5.7), thyroid cancer (3.8; 95% CI, 2.7 to 5.1), and melanoma (

51 oid nodules, diffuse (18)F-FDG uptake, known thyroid cancer, abnormalities adjacent to the thyroid, a

52 nase inhibitors are effective treatments for thyroid cancers, acting primarily as antiangiogenic agen

53 ion analysis on 2003-2016 incidence rates of thyroid cancer, adjusting for distance from Mount Etna,

54 ions that are improving the understanding of thyroid cancer aetiology.

55 All individuals with suspected thyroid cancer after clinical examination in the validat

56 Conclusion: In hemodialysis patients with thyroid cancer, an (131)I activity approximately 30% low

57 ultrasound images from 17 627 patients with thyroid cancer and 180 668 images from 25 325 controls f

58 ndicating lower thyroid function) on risk of thyroid cancer and goiter.

59 pecific recommendations exist for follicular thyroid cancer and Hurthle cell carcinoma in evidence-ba

60 for targeting the sodium-iodine symporter in thyroid cancer and nonthyroidal neoplasms as well as a b

61 us on radioiodine therapy for differentiated thyroid cancer and peptide receptor radionuclide therapy

62 s of persons treated for well-differentiated thyroid cancer and persons with no surgery or surveillan

63 2-5p and MIR20a-5p were upregulated in human thyroid cancer and thyroid cancer experimental models an

64 surance who were admitted to a hospital with thyroid cancer and underwent a thyroidectomy between 200

65 in a patient who had radioiodine-refractory thyroid cancer and who underwent a redifferentiation tre

66 ssion was particularly induced in aggressive thyroid cancers and in patients who had poorer outcomes

67 and inflammation in papillary and follicular thyroid cancers and the presence of multipotent mesenchy

68 mutations are commonly found in melanoma and thyroid cancers and to a lesser degree in other tumor ty

69 , test accuracy to detect thyroid nodules or thyroid cancer, and harms resulting from screening (incl

70 ween ICAM-1 overexpression and malignancy in thyroid cancer, and have pioneered the use of ICAM-1 tar

71 least 1 (131)I treatment for differentiated thyroid cancer, and were responding regarding their last

72 RET mutations occur in 70% of medullary thyroid cancers, and RET fusions occur rarely in other t

73 at results in the identification of indolent thyroid cancers, and treatment of these overdiagnosed ca

74 primarily related to increases in papillary thyroid cancer (annual percent change, 4.4% [95% CI, 4.0

75 The majority of thyroid cancers are differentiated cancers with excellen

76 The great majority of thyroid cancers are of the non-medullary type.

77 atified analyses showed an increased risk of thyroid cancer associated with the E-DII among Southern

78 Anaplastic thyroid cancer (ATC) is a rare malignancy that accounts

79 Background Anaplastic thyroid cancer (ATC) is aggressive with a poor prognosis

80 Anaplastic thyroid cancer (ATC) is one of the most aggressive human

81 lines, 3 melanoma cell lines, 20 anaplastic thyroid cancer (ATC) tumors, and 23 melanoma tumors and

82 all cell lung cancer (NSCLC), and anaplastic thyroid cancer (ATC), making BRAF a desirable target for

83 ptoms or to individuals at increased risk of thyroid cancer because of a history of exposure to ionis

84 Eligible patients diagnosed with thyroid cancer between January 1, 2014, and December 31,

85 ck genes are abnormal in well-differentiated thyroid cancer but not in the benign nodules or a health

86 are high in several human cancers, including thyroid cancer, but ADAR1 editase-dependent mechanisms g

87 models to improve the diagnostic accuracy of thyroid cancer by analysing sonographic imaging data fro

88 nism, chemical concentrations, and papillary thyroid cancer case status.

89 The incidence of detected thyroid cancer cases has been increasing in the United S

90 d carcinomas (PTCs) account for 90% of human thyroid cancer cases, which represent 1% of all cancer c

91 n these estimated doses and the PBLS and FSS thyroid cancer cases.

92 nctional investigations using the anaplastic thyroid cancer cell line CAL-62 found that siRNA against

93 ell proliferation and invasion of follicular thyroid cancer cell line, FTC-133 cells.

94 ined the antitumor effects of CMLD-2 in four thyroid cancer cell lines (SW1736, 8505 C, BCPAP and K1)

95 extracellular superoxide dismutase (SOD3) in thyroid cancer cell lines although according to recent d

96 eptor expression was confirmed in a panel of thyroid cancer cell lines at the mRNA and protein levels

97 Using a panel of thyroid cancer cell lines expressing clinically relevant

98 We sequenced 30 exons of the mTOR gene in 12 thyroid cancer cell lines, 3 melanoma cell lines, 20 ana

99 mens, particularly the anaplastic histotype, thyroid cancer cell lines, and rodent models of thyroid

100 apoptosis in a panel of BRAF- and RAS-mutant thyroid cancer cell lines.

101 e in RAI-refractory papillary and follicular thyroid cancer cell lines.

102 D-2 produced a significant downregulation in thyroid cancer cell viability, coupled to an increase in

103 eractions between fibroblasts and anaplastic thyroid cancer cells contribute to thyroid carcinogenesi

104 Thyroid cancer cells expressing a paired box 8 (PAX8)-PP

105 essential for proliferation and survival of thyroid cancer cells harboring PI3K-activating mutations

106 p27 expression and potentiated apoptosis in thyroid cancer cells while not affecting survival in nor

107 ith soluble factors secreted from anaplastic thyroid cancer cells, compared to the fibroblasts in mon

108 ned activity against its target gene ZEB1 in thyroid cancer cells, likely explaining the reduced aggr

109 ng transwells as well as by using anaplastic thyroid cancer cells-derived conditioned media.

110 ersonal silicone wristband samplers within a thyroid cancer cohort.

111 er a 2-fold increased prevalence (OR 2.7) of thyroid cancer compared to PTEN-associated CS but 50% de

112 CS but 50% decreased prevalence (OR 0.54) of thyroid cancer compared to SDHx-associated CS.

113 ved specificity in identifying patients with thyroid cancer compared with a group of skilled radiolog

114 Sortilin was overexpressed in thyroid cancers compared with benign thyroid tissues (P

115 p75(NTR) was overexpressed in anaplastic thyroid cancers compared with papillary and follicular s

116 TrkA was detected in 20% of thyroid cancers, compared with none of the benign sample

117 wed by its more common counterpart-papillary thyroid cancer-despite its unique biological behaviour a

118 Thyroid cancer development and local invasion were delay

119 Patients with metastatic differentiated thyroid cancer (DTC) may be prepared using either thyroi

120 ve iodine ((131)I) therapy in differentiated thyroid cancer (DTC) patients requiring a completion tre

121 everal susceptibility loci of differentiated thyroid cancer (DTC) were identified by previous genome-

122 tients harboring metastasized differentiated thyroid cancer (DTC); identify suitable treatment regime

123 inherited genetic syndromes associated with thyroid cancer (eg, familial adenomatous polyposis), or

124 were upregulated in human thyroid cancer and thyroid cancer experimental models and their effects on

125 n p27 reorganizes the effects of TGF-beta in thyroid cancer, explaining the slow proliferation but la

126 Conclusion In a mouse model of anaplastic thyroid cancer, ferumoxytol MRI showed 136% +/- 88 great

127 id cancer manifests as familial nonmedullary thyroid cancer (FNMTC), whereas low-penetrance hereditar

128 repair genes were associated with subsequent thyroid cancer for those treated with neck RT >= 30 Gy (

129 16] years; 58213 [75%] women) diagnosed with thyroid cancer from 1974-2013, papillary thyroid cancer

130 patients in the United States diagnosed with thyroid cancer from 1974-2013, the overall incidence of

131 All eligible patients diagnosed with thyroid cancer from 2014 to 2015 from the Georgia and Lo

132 cific in vivo data are limited in follicular thyroid cancer (FTC), a PI3 kinase-driven tumor.

133 hether the increasing incidence of papillary thyroid cancer has been related to thyroid cancer mortal

134 An increased incidence of thyroid cancer has been reported in the area close to Mo

135 cer, whereas the incidence of advanced-stage thyroid cancer has increased marginally.

136 Most cases of thyroid cancer have a good prognosis; the 5-year surviva

137 ibition as valid antineoplastic treatment in thyroid cancer, highlighting MAD2 as a novel therapeutic

138 cer is the second most common differentiated thyroid cancer histological type and has been overshadow

139 O1 expression is significantly higher in all thyroid cancer histotypes compared with normal thyroid a

140 Furthermore, patients with sporadic thyroid cancer homozygous for rs965513[A] demonstrated h

141 ation was associated with increased risks of thyroid cancer [HR per 5 nmol/L higher concentration 1.1

142 missions from the volcano is associated with thyroid cancer in 186 municipalities from three province

143 roid cancer screening and treatment of early thyroid cancer in asymptomatic adults to inform the US P

144 e on the benefits and harms of screening for thyroid cancer in asymptomatic adults, the diagnostic ac

145 The USPSTF recommends against screening for thyroid cancer in asymptomatic adults.

146 gs could explain the increased prevalence of thyroid cancer in CS patients with SDHx germline mutatio

147 per insight into the genetic contribution to thyroid cancer in different populations.

148 iodine ((131)I) therapy may be used to treat thyroid cancer in end-stage renal disease patients who u

149 insurance had lower thyroidectomy rates for thyroid cancer in Massachusetts and the control states c

150 atment of metastatic melanoma and anaplastic thyroid cancer in patients with confirmed BRAF(V600E)/K

151 e pioneering use of (131)I in differentiated thyroid cancer in the 1940s, remarkable achievements in

152 Task Force recommends against screening for thyroid cancer in the general, asymptomatic adult popula

153 levels is associated with a reduced risk of thyroid cancer in the UK Biobank and three other indepen

154 In 2013, the incidence rate of thyroid cancer in the United States was 15.3 cases per 1

155 nt with a true increase in the occurrence of thyroid cancer in the United States.

156 ecific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models.

157 with previously treated RET fusion-positive thyroid cancer, in a phase 1-2 trial of selpercatinib.

158 Annual percent changes in age-adjusted thyroid cancer incidence and incidence-based mortality r

159 To compare trends in thyroid cancer incidence and mortality by tumor characte

160 Thyroid cancer incidence has increased substantially in

161 Papillary thyroid cancer incidence increased for all SEER stages a

162 Thyroid cancer incidence increased, on average, 3.6% per

163 To our knowledge, thyroid cancer incidence is increasing faster than any o

164 s (SEER) registry data to describe trends in thyroid cancer incidence overall and by tumor size in th

165 Research suggests that thyroid cancer incidence rates are increasing, and envir

166 archipelago with one of the highest recorded thyroid cancer incidence rates in the world.

167 h discussed possible factors contributing to thyroid cancer incidence trends worldwide.

168 nome-wide association study of non-medullary thyroid cancer, including in total 3,001 patients and 28

169 cer from 1974-2013, the overall incidence of thyroid cancer increased 3% annually, with increases in

170 he global age-standardized incidence rate of thyroid cancer increased by 20%.

171 Thyroid cancer is a major component cancer of Cowden syn

172 Thyroid cancer is common, yet the sequence of alteration

173 f the remaining undiscovered genetic risk in thyroid cancer is due to rare, moderate- to high-penetra

174 rmined that the net benefit of screening for thyroid cancer is negative.

175 The incidence of thyroid cancer is on the rise, and this disease is proje

176 Anaplastic thyroid cancer is one of the most aggressive thyroid tum

177 The incidence of thyroid cancer is rising steadily because of overdiagnos

178 ermissible activity (MPA) of (131)I to treat thyroid cancer is that which limits the absorbed dose to

179 Thyroid cancer is the most common cancer in Korea.

180 Thyroid cancer is the most common endocrine malignancy.

181 Follicular thyroid cancer is the second most common differentiated

182 but their clinicopathologic significance in thyroid cancer is unclear.

183 is not clear whether active surveillance for thyroid cancer is widely used.

184 y thyroid carcinoma (PTC), the most frequent thyroid cancer, is characterized by low proliferation bu

185 ogy from fine-needle aspiration can identify thyroid cancers, it is unclear if population-based or ta

186 of an antitumour immune response in advanced thyroid cancers linked to cytotoxic T cells and NK cells

187 of hypothyroidism and decreases the risk of thyroid cancer, lymphoma, and a range of proliferative c

188 Highly penetrant hereditary thyroid cancer manifests as familial nonmedullary thyroi

189 r (FNMTC), whereas low-penetrance hereditary thyroid cancer manifests as sporadic disease and is asso

190 adigm of active surveillance in prostate and thyroid cancers might be valuable in informing the devel

191 Thyroid cancer morbidity and mortality, test accuracy to

192 ly, with increases in the incidence rate and thyroid cancer mortality rate for advanced-stage papilla

193 papillary thyroid cancer has been related to thyroid cancer mortality trends.

194 Medullary thyroid cancer (MTC) can be caused by germline mutations

195 ls targeting a Drosophila model of Medullary Thyroid Cancer (MTC) characterized by a transformation n

196 Patients with metastatic medullary thyroid cancer (MTC) have limited systemic treatment opt

197 l involving patients with advanced medullary thyroid cancer (MTC) to assess the efficacy and safety o

198 ncer (AJCC) TNM staging system for medullary thyroid cancer (MTC).

199 lary thyroid cancer (n = 341) and follicular thyroid cancer (n = 25) patients, sex, length of hypothy

200 bgroup analyses were performed for papillary thyroid cancer (n = 341) and follicular thyroid cancer (

201 zed with immunohistochemistry in a cohort of thyroid cancers (n = 128) and compared with adenomas and

202 ulating the presence of non-radioiodine-avid thyroid cancer nodules, and high accumulation in normal

203 se domain are oncogenic drivers in papillary thyroid cancer, non-small-cell lung cancer, and multiple

204 gic type (64625 cases), and 2371 deaths from thyroid cancer occurred during 1994-2013.

205 internal radiation dosimetry, in humans with thyroid cancer, of (18)F-tetrafluoroborate ((18)F-TFB),

206 good prognosis; the 5-year survival rate for thyroid cancer overall is 98.1%.

207 reening are now being observed in those with thyroid cancer, owing to the introduction of new imaging

208 advances are yielding critical insights into thyroid cancer pathogenesis, which are being leveraged f

209 perceptrons, using data from large groups of thyroid cancer patients (between 6,756 and 20,344 for di

210 While the majority of thyroid cancer patients are easily treatable, those with

211 Surgeons and endocrinologists identified by thyroid cancer patients from the Surveillance, Epidemiol

212 del achieved high performance in identifying thyroid cancer patients in the validation sets tested, w

213 regarding hospital release of differentiated thyroid cancer patients treated with (131)I since the pu

214 o showed improved performance in identifying thyroid cancer patients versus skilled radiologists.

215 iric fixed RAI activity in the management of thyroid cancer patients with RAI-avid distant metastases

216 points were examined retrospectively for 65 thyroid cancer patients, referred to determine (131)I up

217 largest subgroup, that is, female papillary thyroid cancer patients.

218 taining clinical features from de-identified thyroid cancer patients.

219 Adjuncts and Approaches Laryngology Familial Thyroid Cancer, Postoperative Care and Complications, Ca

220 ches to Thyroidectomy, Laryngology, Familial Thyroid Cancer, Postoperative Care and Complications, Ca

221 Despite certain unique aspects of follicular thyroid cancer presentation and prognosis, no specific r

222 explain the clinically observed decrease in thyroid cancer prevalence in patients with co-existent P

223 iously identified c-Src as a key mediator of thyroid cancer pro-tumorigenic processes and a promising

224 ADAR1 editase-dependent mechanisms governing thyroid cancer progression are unexplored.

225 ed A-to-I editing as an important pathway in thyroid cancer progression, and highlight RNA editing as

226 fy whether aggressive histology of papillary thyroid cancer (PTC) impacts overall survival (OS).

227 Papillary thyroid cancer (PTC) is the most common type of endocrin

228 lymorphisms (SNPs) associated with papillary thyroid cancer (PTC) risk.

229 lti-generation CS-like family with papillary thyroid cancer (PTC), applying a combined linkage-based

230 ctor in the risk stratification of papillary thyroid cancer (PTC), but whether this is generally appl

231 rine model of Braf(V600E) -induced papillary thyroid cancer (PTC).

232 ) in non-carcinogenic thyroids and papillary thyroid cancer (PTC).

233 promoter mutations can coexist in papillary thyroid cancer (PTC).

234 ith clinically node negative (cN0) papillary thyroid cancer (PTC).

235 umors, including MNG, schwannomas, papillary thyroid cancers (PTCs), and Wilms tumors.

236 ; P < .001; melanoma: R = 0.36; P = .01; and thyroid cancer: R = 0.30; P = .03).

237 ng been associated with the thyroid and with thyroid cancers, raising seminal questions about the rol

238 South-East was associated with a decrease in thyroid cancer rates in the whole population (- 0.67 cas

239 echanisms by which tumor-stroma crosstalk in thyroid cancer remains poorly characterized.

240 ancreatitis, pancreatic cancer, or medullary thyroid cancer reported between GLP-1 receptor agonist t

241 trials of patients with well-differentiated thyroid cancer reported in 2012 (HiLo and ESTIMABL1) fou

242 ancers, non-Hodgkin lymphomas, and medullary thyroid cancers represent novel indications for the in v

243 histological confirmation of differentiated thyroid cancer requiring radioactive iodine ablation (pe

244 AF in patients with medullary and anaplastic thyroid cancers, respectively.

245 mined the association between differentiated thyroid cancer risk and the energy-adjusted Dietary Infl

246 Positive associations between E-DII and thyroid cancer risk were observed (comparing extreme ter

247 and low-penetrance genetic factors increase thyroid cancer risk.

248 f human poorly differentiated and anaplastic thyroid cancers screened by next-generation sequencing u

249 eview the benefits and harms associated with thyroid cancer screening and treatment of early thyroid

250 s (n = 5894) directly addressed the harms of thyroid cancer screening, none of which suggested any se

251 ity studies directly examined the benefit of thyroid cancer screening.

252 tochondrial genomes in renal chromophobe and thyroid cancers show particularly strong signals of posi

253 Papillary thyroid cancer-specific mortality for cases with both mu

254 Papillary thyroid cancer-specific mortality occurred in 4 of 629 p

255 This study aimed to assess the overall and thyroid cancer-specific survival in a large cohort of pa

256 , sex, primary malignancy, overall survival, thyroid cancer-specific survival, FNA, and histopatholog

257 ndifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofib

258 sociated methylation differences between the thyroid cancer subtypes were linked to differential gene

259 e to distinguish between two uterine and two thyroid cancer subtypes.

260 markedly enriched in kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the a

261 ed to approximately 25,000 members of ThyCa: Thyroid Cancer Survivors' Association, Inc., and was ava

262 Methods: Data were tabulated from a Thyroid Cancer Survivors' Association, Inc., survey emai

263 long noncoding RNA (lncRNA) gene, papillary thyroid cancer susceptibility candidate 2 (PTCSC2).

264 ing the associations of these compounds with thyroid cancer (TC) is lacking.

265 (RAI) treatment in patients with metastatic thyroid cancer (TC) is still a matter of debate.

266 Thyroid cancer (TC) is the most frequently occurring can

267 d a gene expression signature from zebrafish thyroid cancer that is predictive of disease-free surviv

268 F and PTTG have a critical role in promoting thyroid cancer that is predictive of poorer patient outc

269 ) knock-in (PV) mice that develop metastatic thyroid cancer that most closely resembles FTC.

270 n, to examine incidental findings related to thyroid cancer (ThCa).

271 ter than small, given the relative rarity of thyroid cancer, the apparent lack of difference in outco

272 with previously treated RET fusion-positive thyroid cancer, the percentage who had a response was 79

273 In patients with RET-altered thyroid cancers, the efficacy and safety of selective RE

274 current knowledge of the immune response in thyroid cancers, the latest and ongoing immune-based app

275 the management of patients with prostate and thyroid cancers; the evidence of overdiagnosis and overt

276 ensively review the literature on follicular thyroid cancer to provide an evidence-based guide to the

277 rly data are now accumulating in progressive thyroid cancers treated with single-agent ICB therapies

278 the association of insurance expansion with thyroid cancer treatment using the 2006 Massachusetts he

279 Change in the thyroidectomy rate for thyroid cancer treatment was the primary outcome evaluat

280 in thyroid physiology and radioiodide-based thyroid cancer treatment, also transports the environmen

281 he 2006 Massachusetts health care reform and thyroid cancer treatment, and participants were controll

282 SCs with a fibrotic fingerprint in papillary thyroid cancer tumors and the autocrine-paracrine conver

283 well-differentiated and in undifferentiated thyroid cancer types but not in normal thyrocytes and be

284 ning set and only individuals with suspected thyroid cancer underwent pathological examination to con

285 For many patients with differentiated thyroid cancer, use of radioactive iodine (RAI) does not

286 We extended our findings to human thyroid cancer using TCGA data sets (n=322) and found st

287 y of core-needle biopsy for the diagnosis of thyroid cancer was low (42.8%) because the technique was

288 ith thyroid cancer from 1974-2013, papillary thyroid cancer was the most common histologic type (6462

289 CALCA, a biomarker for medullary thyroid cancer, was hypersecreted in metastatic pancreat

290 cohort of patients with well-differentiated thyroid cancer (WDTC) treated or not with radioactive io

291 ress the importance of RNA A-to-I editing in thyroid cancer, we examined the role of ADAR1.

292 scans of 5 subjects with recently diagnosed thyroid cancer were acquired before surgery for up to 4

293 s in ablative radioiodine (RAI) treatment of thyroid cancer, where its ability to transport radioisot

294 erentiated papillary subtype and early-stage thyroid cancer, whereas the incidence of advanced-stage

295 In 88 patients with RET-mutant medullary thyroid cancer who had not previously received vandetani

296 enrolled patients with RET-mutant medullary thyroid cancer who had previously received vandetanib, c

297 Among patients with thyroid cancer who have been declared disease free, pref

298 ade toxic effects in patients with medullary thyroid cancer with and without previous vandetanib or c

299 is work details our experience with treating thyroid cancer with iodine in chronic renal failure pati

300 enrolled patients with RET-mutant medullary thyroid cancer with or without previous vandetanib or ca